Institute for Cancer Research

Kjetil Taskén
Institute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports


Current news and events

Review article by the Sandvig group:Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges

Biodistribution, metabolism and excretion studies are important in order to obtain market approval of new products for medical imaging or therapeutic use.

In this review, senior scientists in the Sandvig group at the Department of Molecular Cell Biology, Institute for Cancer Research, discuss the possibilities and challenges with currently available methods with a focus on what is needed to bring such studies in small animals forward in an optimal way. 

The review is published in the prestigious journal Advanced Drug Delivery Research (IF 15.5).

Ceremony in the Oslo University Aula May 9th:King Olav V´s Cancer Research Award for 2022 to Håvard Danielsen

Håvard E. Danielsen
Håvard E. Danielsen

Professor Håvard E. Danielsen is this year’s recipient of the King Olav V's Cancer Research Prize.

He has been awarded the prize for having developed methods using artificial intelligence (AI) that can give cancer patients a more precise prognosis and counteract overtreatment.

His Majesty the King was responsible for the solemn presentation of the award during a ceremony held in the university’s auditorium in Oslo on May 9th 2022.


Publication in Nature Medicine:Norwegian cancer initiatives receive international attention

Kjetil Taskén,
first author
Kjetil Taskén,
first author

The precision cancer medicine ecosystem established in Norway and the ongoing implementation in the health care system are unique in an international context. The description of the entire ecosystem was published in Nature Medicine on May 5th.
“These initiatives represent a triple-win effect,” says first author Kjetil Taskén, Head and Director of Institute of Cancer Research at Oslo University Hospital and Professor at University of Oslo. “The patients gain access to modern treatments; the researchers can investigate the effect of different medicines on new indications; and the industry can expand the application of their drugs.”

Christian Holst Bergsland defended his doctoral thesis

On the 21st of April, the 4x-great-grandchild of Frederik Holst - the first who defended a doctoral thesis in Norway, University of Christiania - Christian Holst Bergsland defended his thesis “Fluorescence-based multiplex immunohistochemistry in precision medicine of colorectal cancer” for the PhD degree at the Faculty of Medicine, University of Oslo.
He received excellent assessment from the committee, both in the written report and during the defense. The first and second opponents were Professors Manuel Salto-Tellez, Institute for Cancer Research, London and Lars Akslen, University of Bergen. Professor Anne Hansen Ree was the chair of the evaluation committee.

Units and subpages

View all subunitsHide all subunits